The plant-based system, called FastPharming, is iBio's proprietary recombinant protein manufacturing platform. According to CEO Tom Isett, it offers a more sustainable method to advance promising candidates from concept to clinic.
Isett spoke with ScienceBoard.net at the 2022 Biotechnology Innovation Organization (BIO) International Convention about the company's technology and programs, the future of plant-made vaccines and therapeutics, COVID-19 vaccine development, as well as the launch of iBio's early drug discovery operations focused on oncology.
"Starting from being a contract development and manufacturing organization, we've moved through to begin producing our own proprietary drugs," Isett said. "We're looking to speed the time to clinic through our manufacturing platforms as well, and one of them is quite novel and unique. We use the power of plants to make glycoproteins, monoclonal antibodies, and vaccine antigens."
Watch the video below to learn more.